Journal for Immunotherapy of Cancer This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
AbstractTumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit ascancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including immune homeostasis and polymorphisms in the major and minor histocompa...
Source: Journal for Immunotherapy of Cancer - May 21, 2019 Category: Cancer & Oncology Source Type: research

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
ConclusionsFor the first time, a listeria vaccine-based immunotherapy was shown to be able to induce a tumor antigen-specific T cell response within the tumor microenvironment of a “cold” tumor such as PDAC and sensitize the tumor to checkpoint inhibitor therapy. Moreover, this combination immunotherapy led to objective tumor responses and survival benefit in the mice with spontaneously developed PDAC tumors. Therefore, our study supports developing Lm-ANXA2 as a therapeut ic agent in combination with anti-PD-1 antibody for PDAC treatment. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - May 21, 2019 Category: Cancer & Oncology Source Type: research

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
ConclusionsICIs produce a spectrum of distinct classes of neurologic AEs that can cause significant morbidity and mortality and tend to occur early and with class-specific associations. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - May 21, 2019 Category: Cancer & Oncology Source Type: research

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer
AbstractPatients with human immunodeficiency virus (HIV) infection have a high risk of developing virally-mediated cancers. These tumors have several features that could make them vulnerable to immune checkpoint inhibitors (ICIs) including, but not limited to, increased expression of the CTLA-4 and PD-1 checkpoints on their CD4+ T cells. Even so, HIV-positive patients are generally excluded from immunotherapy cancer clinical trials due to safety concerns. Hence, only case series have been published regarding HIV-positive patients with cancer who received ICIs, but these reports of individuals with a variety of malignancies...
Source: Journal for Immunotherapy of Cancer - May 21, 2019 Category: Cancer & Oncology Source Type: research

The promise of Immuno-oncology: implications for defining the value of cancer treatment
AbstractThe rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Responding to ongoing efforts to generate value assessments for novel therapies, multiple stakeholders have been considering the question of “What makes I-O transformative?” Evaluating the distinct features and attributes of these therapies, and better characterizing how patients experience them, will inform such assessments. This paper defines ways in which treatment with I-O is different from other ther...
Source: Journal for Immunotherapy of Cancer - May 16, 2019 Category: Cancer & Oncology Source Type: research

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
ConclusionsWe have comprehensively analyzed the early immunogenomic changes induced in ESCC by CCRT and correlated them with clinical outcomes. Our results provide a potential basis for combining immunotherapy with CCRT for the treatment of ESCC. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - May 15, 2019 Category: Cancer & Oncology Source Type: research

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
ConclusionsThis prospective experience of intermittent nivolumab dosing in mRCC supports further investigation of intermittent immunotherapy dosing strategies in RCC.Trial registrationNCT03126331 (Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients; Date of registration 4/27/2017;https://clinicaltrials.gov/ct2/show/NCT03126331). (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - May 15, 2019 Category: Cancer & Oncology Source Type: research

Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare
ConclusionsThis case suggests a potential influence of Th17 cells on the neutrophil recruitment and neutrophil-driven inflammatory events leading to pseudogout induced by immune checkpoint inhibitor therapy. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - May 13, 2019 Category: Cancer & Oncology Source Type: research

Correction to: Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T-cell immunity
Following publication of the original article [1], the author reported the wrong version of Figs.  5 and 7 have been published. The correct version of the figures can be found below: (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - May 6, 2019 Category: Cancer & Oncology Source Type: research

Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade
ConclusionsThese two cases suggest that indels might be a new predictor of PD-1 blockade response for ICC patients beside PD-L1 expression, TMB, MSI, and dMMR, warranting further clinical investigation. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - May 6, 2019 Category: Cancer & Oncology Source Type: research

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates
AbstractThe progression of cancer requires mutational adaptation to permit unrestrained proliferation. A fraction of cancer mutations are oncogenic drivers, while others are putative ‘passengers’ that do not contribute to oncogenesis. However, altered peptides arising from passenger mutations may bind MHCs and activate non-self immunologic signals (i.e. neoantigens), thus requiring immunoediting for cancer persistence. Disruption of antigen processing machinery in tumor cell s may diminish this requirement. Here, we show that rare mutations in antigen processing machinery are associated with high mutational burden and ...
Source: Journal for Immunotherapy of Cancer - May 6, 2019 Category: Cancer & Oncology Source Type: research

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
ConclusionsAn automated CD8xPD-L1 signature may help to identify NSCLC patients with improved response to durvalumab therapy. Our data also support the prognostic value of CD8+ TILS in NSCLC patients who do not receive ICT.Trial registrationClinicalTrials.gov identifier:NCT01693562.Study code: CD-ON-MEDI4736-1108.Interventional study (ongoing but not currently recruiting).Actual study start date: August 29, 2012.Primary completion date: June 23, 2017 (final data collection date for primary outcome measure). (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - May 5, 2019 Category: Cancer & Oncology Source Type: research

Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors
AbstractHigh-risk human papillomavirus (HPV) are responsible for genital and oral cancers associated with the expression of the E6/E7 HPV oncogenes. Therapeutic vaccines targeting those oncogenes can only partially control tumor progression, highlighting the necessity to investigate different treatment strategies. Using the genital orthotopic HPV16 TC-1 model, herein we sequentially investigated in progressively more stringent settings the effects of systemic administration of carboplatin/paclitaxel (C  + P) chemotherapy combined with HPV16-E7 synthetic long peptide (E7LP) vaccination, followed by intravaginal immunost...
Source: Journal for Immunotherapy of Cancer - May 5, 2019 Category: Cancer & Oncology Source Type: research

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis
ConclusionsAvelumab demonstrated safety and clinical activity in patients with laryngeal RRP. Further study of immune checkpoint blockade for RRP, possibly with longer treatment duration or in combination with other immunotherapies aimed at activating antiviral immunity, is warranted.Trial registrationNCT, numberNCT02859454, registered August 9, 2016. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - May 2, 2019 Category: Cancer & Oncology Source Type: research

Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
ConclusionsICI treatment can result in a clinical condition similar to typical acute cholecystitis in a minority of patients. ICI-related cholecystitis should be managed in a similar fashion to typical cholecystitis. The efficacy of steroids for the treatment of ICI-related cholecystitis is unclear. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - May 2, 2019 Category: Cancer & Oncology Source Type: research